Irinotecan dysarthria

Author: apuz

August undefined, 2024

WebBACKGROUND: Irinotecan, a topoisomerase I inhibitor, is a cytotoxic chemotherapeutic agent used to treat multiple malignancies, including those of colorectal, pancreatic, cervical, esophageal, gastric, and lung origin.Dysarthria, a state of difficult or unclear articulation of speech, has been reported as a rare side effect of irinotecan through multiple case … WebJul 8, 2009 · The most frequent side effects of irinotecan include acute cholinergic syndrome (ACS), delayed-onset diarrhoea, and bone-marrow suppression [1]. Much more unusual is the occurrence of irinotecan-induced central nervous system (CNS) toxicity with dysarthria as the predominant symptom.

American Journal of Case Reports Irinotecan-Associated …

WebMar 21, 2024 · Irinotecan (Camptosar ©, CPT-11), a topoisomerase I inhibitor, is a commonly used cytotoxic chemotherapeutic in the treatment of multiple malignancies, particularly of gastrointestinal origin.Dysarthria secondary to irinotecan has been described as a rare side effect in a few case reports with limited data to recommend appropriate … WebJun 28, 2024 · Dysarthria, a state of difficult or unclear articulation of speech, has been reported as a rare side effect of irinotecan through multiple case reports and case … cilwendeg rally 2022 route map

National Center for Biotechnology Information

WebSep 19, 2001 · Irinotecan (CPT-11) is a semisynthetic analogue of camptothecin with antitumor activity in solid neoplasias. Camptothecin inhibits topoisomerase I and impedes the uncoiling of the DNA double helix, thus delaying its replication and cell division. Currently, CPT-11 combined with 5-fluorouracil (5-FU) is used as a first-line treatment of advanced ... WebJul 1, 2008 · Europe PMC is an archive of life sciences journal literature. Irinotecan-based chemotherapy regimens are used worldwide in the treatment of recurrent or advanced gastrointestinal (GI) cancers, in combination with other cytotoxic drugs or monoclonal antibodies. The most common side effects include acute cholinergic syndrome (ACS) mediated through the inhibition … See more A 49-year-old man diagnosed with locally advanced rectal cancer at the end of 2006 was treated with neoadjuvant radiotherapy combined with capecitabine followed by surgery in February 2007. From April to July 2007 he received … See more A 58-year-old man was diagnosed with locally advanced pancreatic adenocarcinoma in October 2013. The patient had a good … See more A 36-year-old woman underwent right hemicolectomy due to adenocarcinoma in July 2009. The pathological stage at diagnosis was … See more In May 2012, a 60-year-old man underwent right hemicolectomy for adenocarcinoma of the right colon. The pathology report showed poorly differentiated adenocarcinoma of the ileocecal valve (stage pT3 N2 M0) … See more dhl westborough ma

Irinotecan-associated dysarthria in patients with pancreatic …

Common and Rare Side Effects for Irinotecan HCL Vial - WebMD

WebJul 23, 2024 · Irinotecan is a topoisomerase-I inhibitor that is commonly used in combination with other chemotherapy agents for gastrointestinal malignancies. It has … WebIrinotecan-associated dysarthria: A single institution case series with management implications in patients with gastrointestinal malignancies Article Mar 2024 David Bing Zhen Rachel L McDevitt... cilwen country house bed and breakfastWebMar 21, 2024 · Irinotecan (Camptosar ©, CPT-11), a topoisomerase I inhibitor, is a commonly used cytotoxic chemotherapeutic in the treatment of multiple malignancies, … dhl west coast

"WebDysarthria, deﬁned as an impairment of speech caused by an alteration of the strength and control of speech muscles, is a very uncommon central nervous system (CNS) adverse … " - Irinotecan dysarthria

Irinotecan dysarthria

National Center for Biotechnology Information

WebMay 1, 2024 · Early diarrhea (occurring during or shortly after infusion of Irinotecan hydrochloride injection) is usually transient and infrequently severe. It may be accompanied by cholinergic symptoms of rhinitis, increased salivation, miosis, lacrimation, diaphoresis, flushing, and intestinal hyperperistalsis that can cause abdominal cramping. WebJun 28, 2024 · Dysarthria, a state of difficult or unclear articulation of speech, has been reported as a rare side effect of irinotecan through multiple case reports and case series, …

Did you know?

Webdysarthria while receiving intravenous infusion of irinotecan. In all our cases, dysarthria occurred during the infusion of the ﬁrst course of irinotecan, and then resolved rapidly without any sequelae. Imaging of the brain was per-formed, but failed to show any evidence of an acute neurological event. We also reviewed the WebJul 26, 2024 · The patient was able to tolerate this reaction and received 20 cycles of irinotecan-based chemotherapy despite experiencing the muscle twitching with every cycle at the same onset, duration, and severity. It is possible that competitive metabolism by concomitant medications metabolized by CYP3A4 or UGT1A1 was responsible for this …

WebJan 19, 2013 · Irinotecan. A 34-year-old man with metastatic sarcoma and a 63-year-old woman with disseminated adenocarcinoma developed CNS toxicity with dysarthria during treatment with irinotecan. The woman also experienced an acute cholinergic syndrome. The man, who had experienced partial remission of his sarcoma following antineoplastic … WebNational Center for Biotechnology Information

WebApr 1, 2024 · Irinotecan-induced dysarthria has been reported in the literature, but the underlying mechanism of this neurotoxicity remains unclear. Here, we present a 35-year-old female with metastatic colon cancer who experienced dysarthria during irinotecan infusion. Webby Irinotecan in the form of dysarthria is an uncommon adverse event in which the pathologic mechanism has not been fully elucidated. Dysarthria is a motor speech disorder characterized by problems with articulation, phonetics and prosody. It can be caused by central or peripheral nervous system damage leading to the loss of control of the

WebCase Series of Irinotecan-Induced-Dysarthria: A Review of Literature and Proposition of a Pre-Medication Regimen. Mathews J Gastroenterol Hepatol 4(1): 13. 2 regimen. Through a retrospective and ...

WebJan 18, 2012 · Irinotecan is a prodrug that requires in vivo activation by carboxylesterases to yield its active and potent metabolite, SN-38, which works in a cell cycle phase-specific (S phase) mechanism to... cilwendeg road rally escortWebJan 18, 2012 · Irinotecan is a prodrug that requires in vivo activation by carboxylesterases to yield its active and potent metabolite, SN-38, which works in a cell cycle phase-specific (S … cilwendeg rally 2022WebJul 1, 2013 · Summary A 49-year-old man with meta-static colon cancer undergoing treatment with i.v. irinotecan (180 mg/m 2 to be infused over 120 minutes) as part of a … dhl westborough ma telephoneWebJan 18, 2012 · In conclusion, selective irinotecan-induced dysarthria is an unusual and impressive entity, which can occur within minutes of irinotecan infusion. It is potentially related to a relative cholinergic oversensitivity of neurons in the area of the nucleus of the hypoglossal nerve. Though atropine can decrease cholinergic symptoms, it has not been ... cilwendeg results 1985WebMay 17, 2024 · Signs and symptoms of dysarthria vary, depending on the underlying cause and the type of dysarthria. They may include: Slurred speech. Slow speech. Inability to … cil weslacoWebSep 12, 2024 · Hence irinotecan may cause overstimulation of hypoglossal nerve leading to dysarthria. Oxaliplatin is known to potentiate the cholinergic effects of irinotecan by causing neuronal... cilwendeg rally resultsWebAbstract. Irinotecan (Camptosar ©, CPT-11), a topoisomerase I inhibitor, is a commonly used cytotoxic chemotherapeutic in the treatment of multiple malignancies, particularly … cilwendeg lodge boncath